Neogene Therapeutics
Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid cancers
Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid cancers
Neogene Therapeutics, with a slogan of "Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid cancers," is a global, clinical-stage biotechnology company founded in 2018. The company is focused on the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers. With headquarters in The Netherlands, and offices in Santa Monica, CA and Amsterdam, the company is aiming to change the paradigm of treatment for solid cancers. Neogene is a member of the AstraZeneca Group. The company recently secured a significant $110.00M Series A investment on 14 September 2020 from a consortium of prominent investors including Polaris Partners, Pontifax, Bellco Capital, EcoR1 Capital, Jeito Capital, Syncona Investment Management, Two River, Vida Ventures, and TPG. Neogene Therapeutics operates within the industries of Biotechnology, Health Care, Health and Wellness.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $110.00M | 9 |
|
14 Sep 2020 |
| Venture Round | $15.00M | - | 23 May 2019 |
No recent news or press coverage available for Neogene Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
